Validity of Celebrex Patents Upheld In Court, Barring Generics Until 2015
This article was originally published in The Pink Sheet Daily
Executive SummaryANDA filer Teva says it will appeal a federal court decision over the COX-2 inhibitor.
You may also be interested in...
Pfizer sues five generic firms alleging their celecoxib ANDAs infringe a reissued method-of-use patent, which protects the blockbuster COX-2 inhibitor until December 2015, 18 months longer than had been expected.